Targeted Delivery of Macrophage Membrane Biomimetic Liposomes Through Intranasal Administration for Treatment of Ischemic Stroke [Corrigendum]

Abstract

Liu T, Zhang M, Zhang J, Kang N, Zheng L, Ding Z. Int J Nanomedicine. 2024;19:6177–6199. Page 6181, Animals section, last sentence, the text “All animal procedures were performed in compliance with the China National Institute’s Guidelines on the Care and Use of Laboratory and were approved by the Animal Experimental Ethics Committee of Jilin University (Approval No. 20210069)” should read “All animal procedures were performed in compliance with the China National Institute’s Guidelines on the Care and Use of Laboratory and were approved by the Animal Experimental Ethics Committee of Jilin University (Approval No. 20210069 and 20220081)”. In addition, the authors have advised Figure 2C on page 6186 is incorrect. Due to an error at the time of figure assembly the images in Non-activated hCMEC/D3 MM-Lip-RhB and Activated hCMEC/D3 Lip-RhB were duplicated. The correct Figure 2 is as follows. Figure 2 Inflammatory response and release profile of MM-Lipo in vitro. (A) The effect of LPS concentration on hCMEC/D3 cells survival rate. (B) ICAM-1 of hCMEC/D3 cells before and after LPS stimulation. (C) Fluorescence confocal images show the binding of DiD-labeled liposomes (red) to inflamed hCMEC/D3 cells stained by DAPI (blue). hCMEC/D3 cells were activated with LPS /without LPS (scalebar: 30 μm). The data were presented as the mean ± SD (n =3). The authors apologize for these oversights.

Keywords

• Macrophage-membrane coating
• Biomimetic liposome
• Brain targeting
• Ischemic stroke
• intranasal delivery